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There is increasing evidence that outcomes of health care differ by patient characteristics, such as gender and
ethnicity. If evidence-based medicine is to improve quality of care for all patients, it is essential to take this diversity
into account when designing clinical studies. So far, this notion has mainly been translated into recommendations
for including minority populations in trials. We argue that a more comprehensive view of the production of
diversity-sensitive clinical evidence is needed, one that takes heterogeneity as a starting point in research. We call
for a mix of methodological approaches aimed at identifying diversity issues that matter and analysing the impact
of these diversities on clinical outcomes. Institutional changes are necessary to support this methodological reform.
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Evidence-based medicine (EBM) is the conscientious,
explicit, and judicious use of current best evidence in
making decisions about the care of individual patients
[1]. The main aim has been to ground medical decision-
making in high-quality evidence, with the ultimate aim
of improving quality of care. Randomized controlled tri-
als (RCTs) that show whether a treatment is efficacious
represent the gold standard in EBM. Originally, RCTs
were thought to produce knowledge applicable to all pa-
tients. More recently, this assumption has been criticized
[2-4]. There is increasing evidence that treatment out-
comes as well as disease progression and manifestation
might vary between patient groups. Examples include
the different way that black patients respond to specific
antihypertensive drugs [5], and sex differences in the
epidemiology of heart disease [6]. If EBM is to improve
quality of care for all patients, when designing clinical
studies it is essential to consider diversity in the efficacy
of treatments and the aetiology and manifestation of dis-
eases. Diversity in clinical research is thus a prerequisite
for equity in health [7,8].* Correspondence: k.stronks@amc.uva.nl
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reproduction in any medium, provided the orRegulatory reforms in the mid-1990s, particularly those
in the USA, drew attention to this issue [4]. These regula-
tory reforms appear to have led mainly to greater represen-
tation of women, the elderly, and ethnic minorities in trial
populations. In fact, a whole new field of study has devel-
oped, labelled by Epstein [9] as ‘recruitmentology’: empir-
ical studies that evaluate the effectiveness of recruitment
strategies for including people from minority populations.
An example of this is the Eliminating Disparities in Clinical
Trials (EDICT) Project, which aimed to develop and im-
plement policy solutions to promote the inclusion of mi-
nority populations in clinical trials [10]. This resulted in a
broad range of recommendations, from professional educa-
tion to community involvement in the process of designing
a clinical trial.
However, only some of these studies have the potential
for subgroup analysis, which is a prerequisite for assessing
differences in treatment outcomes between groups. For
example, after looking at 86 original articles in medical
journals that reported on clinical trials funded by the
National Institutes of Health (NIH), Geller et al. [11] con-
cluded in 2011 that only 25% of the studies reported sex-
specific results, and less than half of the studies analysed
the results by ethnic group. In most cases, the ethnic
minority groups were too small to allow for subgroup ana-
lysis. In fact, the authors found very few improvementsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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earlier. As a result, 20 years after the introduction of
regulatory reforms calling for analysis by age, sex, and
ethnicity, there is still little evidence on diversity in the effi-
cacy of treatment, leading to a lack of diversity-sensitive
guidelines for professionals.
The challenges are great. A multidisciplinary project
commissioned by the Netherlands Organisation for Health
Research and Development (ZonMw) - involving cli-
nicians, epidemiologists, ethicists, sociologists, and an-
thropologists - examined factors that both facilitate
and constrain a focus on diversity in clinical research.
The project included a number of literature reviews, and a
conference in which the conclusions of these reviews were
discussed [12]. Based on this project, in this paper we put
forward recommendations on the methodology and insti-
tutional mechanisms that can facilitate a systematic and
comprehensive production of diversity-sensitive evidence.
Before presenting these recommendations, we will first
make the case for the importance of having a comprehen-
sive view of diversity that goes beyond merely including
minority populations in clinical trials.
Review
Framing the issue of diversity in the production of clinical
evidence
From an epistemological view, homogeneity is the dom-
inant paradigm in clinical research. This is apparent from
the methodology of clinical trials: strict inclusion and
exclusion criteria are set for clinical trials to minimize
the chance of side effects, comorbidity, and early dropout
[13]. Homogeneity of the population to be studied is con-
sidered important, as it improves a trial’s internal validity
and statistical power [13].
Consequently, diversity issues are frequently framed as
deviations from the homogeneous population. Given the
under-representation of ethnic minorities, women, and
older people, this generally means that these are devia-
tions from the white male population. But this does not
mean that diverse groups (as defined by sex, ethnicity, or
other background characteristics) are always different
from each other with respect to health or medical care.
On the contrary, the literature contains many examples
of studies showing that the effects of clinical interven-
tions do not differ between subgroups. Well-known ex-
amples include the use of aspirin to prevent coronary
heart disease, which is now thought to be as effective in
women as in men, despite the results of previous trials
pointing to its ineffectiveness in women [14,15].
However, deliberating about populations that may or
may not differ from the standard population will in itself
not be enough to ensure a thorough understanding of
inequalities between populations. The limitations of this
approach are twofold. First, it looks at diversity issuesfrom the perspective of the standard only (such as ‘male
patients’). For example, this has led to an emphasis on
the specific health risks faced by women (related to their
different reproductive system, et cetera.). In this perspec-
tive, the specific health risks faced by men are likely to
be neglected. If we take gender sensitivity rather than
deviations from the male norm as a starting point for
analysis, this might draw our attention to characteristics
such as the attitudes and values that underlie differences
between genders, including masculinity and caring cap-
acities [16,17]. Second, background characteristics such
as age, sex, and ethnicity do not in themselves have
aetiological consequences. In defining diversity issues
that matter, studies should in fact consider a broad range
of relevant factors, including biological, genetic, socio-
cultural, psychological, economic, and behavioural fac-
tors which may have impact on the efficacy of health
care services and the health of individuals. This explor-
ation goes far beyond the influences of variables that
have traditionally been used to distinguish between
groups of patients (such as ‘ethnicity’), which function as
surrogate classifiers of relevant biomedical and sociocul-
tural differences [18]. For example, in osteoporosis, an
important sex difference in bone loss is related to the
mechanisms of bone deterioration [19]. Thus, studying
the efficacy of medication on these different mechanisms
rather than the differences between sexes is likely to
provide knowledge that is highly relevant to the treat-
ment for various patient groups. A more nuanced under-
standing of differences and similarities between people is
thus likely to address the underlying biological and/or
sociocultural mechanisms.
If we are to take the principle of diversity-sensitive
clinical knowledge seriously, it needs to be made the
core perspective in study design, starting with the
conceptualization of the problem to be studied. This
requires that the hypotheses underlying studies based
on a nuanced understanding of possible differences
between groups should be studied in a population that
represents groups that differ on the aspects considered
to be relevant. This will help to produce clinical know-
ledge that can be applied to the entire population, as it
allows for a detailed understanding of why a specific
intervention works and for whom. As such, producing
diversity-sensitive clinical knowledge is also likely to
benefit the standard population to which trials are usu-
ally restricted.
Towards a methodological reform
What are the implications for clinical research method-
ology if we take heterogeneity as the guiding principle?
RCTs can, of course, be used to study heterogeneity. If
the effect of the intervention under study is hypothesized
to differ between subgroups, such as the hypothesis that
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women, there are two options. First, new RCTs can be
designed that specifically test treatment effects in relevant
subgroups, as was done in the Women’s Health Initiative,
which critically examined the existing evidence on the pre-
ventive effects of hormone replacement therapy on cardio-
vascular disease [20]. A second option is to enlarge the
original trial with sufficient members from each subgroup,
so that the potential differential effect - called effect modifi-
cation in epidemiological terms - can be studied. This
implies the a priori creation of a subgroup, driven by
specific hypotheses as to differences in treatment effect. In
addition, the subgroups should be appropriately powered
to detect the hypothesized effect size difference [21].
When aiming to include subgroups that are traditionally
under-represented in clinical trials, many problems might
be encountered in terms of adequate trial enrolment, the
validity of measurements (including self-reported measure-
ments) in different groups, and compliance and retention
(for example, in ethnic minority groups) [22]. In view of
the methodological literature, it appears that the majority
of these problems can be overcome in principle. Effective
strategies for this are targeted communication, and antici-
pating the cultural and cognitive characteristics of specific
populations [23-26]. To create conditions for heteroge-
neous study populations, it is essential to further develop
instruments and strategies that suit the needs of those
minority populations that are difficult to recruit with the
available instruments [26].
However, this does not imply that all clinical trials should
automatically include subgroups. Ensuring the inclusion of
subgroups large enough to allow for subgroup analysis has
an enormous impact on costs. In view of limited resources,
the choice for a heterogeneous study population should at
least be weighed against the strength of the indications for
the presence of diversity in health outcomes. This implies
that confronting diversity in clinical research starts with
formulating hypotheses as to why diversity does or does
not matter in a specific case.
To identify the diversity issues that matter for health
outcomes, a mix of different methodologies is needed. An
increasing number of complementary research methods
are available as shown below.
Reanalysis of past trials: researchers can critically
review past trials, exploring unexpected phenomena in
RCTs and identifying variance in effects, such as outliers.
Meta-analysis at an individual level can be used to
explore differences in treatment outcomes by subgroup.
A meta-analysis on the effects of chemoradiotherapy for
cervical cancer in subgroups of women by patient
variables could serve as an example [27]. Of course, we
acknowledge the weaknesses of subgroup analysis. The
most important downside of this strategy is the risk that
in the case of multiple subgroup analyses, a differencefrom the overall results will be found in one or more
comparisons even if none exists (type 1 error). However,
from an equity perspective, ‘rejecting all such analyses
may risk throwing the baby out with the bathwater’, as
argued by Petticrew et al. [21].
Observational studies: researchers can review the in-
creasing number of biomedical and pharmacodynamic
studies that reveal how aetiology, prognosis, disease per-
ception, and/or effects of interventions are affected by
age, sex and/or ethnicity and by other factors [28,29],
or the intersectionality between these factors [17,30],
supported by the development of statistical methods
to establish causality [31]. In addition, population-based
observational studies can be used to explore a wide range
of possible associations between diversity variables and
treatment outcome, on their own merits and for generating
hypotheses for the relevant RCTs. For example, population
studies on the contraceptive pill have identified smoking
and age as relevant dimensions of diversity associated with
the risk for thrombosis [32]. It should be acknowledged,
however, that the problem of under-representation of
groups such as ethnic minority populations, as discussed
earlier in terms of clinical trials, apply equally to observa-
tional studies. For example, in their 2006 review of 72
cardiovascular cohort studies, Ranganathan and Bhopal
concluded that only 15 of these were able, by design,
to compare different ethnic groups. All of these were
performed in the USA. Of the 41 studies in Europe, none
was able to provide data by ethnic group [33], which limits
their usability for generating diversity hypotheses. In-
vestments are warranted to increase usability so that
aetiological and epidemiological knowledge can be pro-
duced based on observational studies that also assume
heterogeneity.
Databases of routine health care: researchers can con-
sult databases of patients registered with, for example, a
general practitioner for routine health care, to explore
effect modification in treatment outcomes. Databases of
adverse drug reaction reports may also be relevant. An
analysis of a population-based birth defect registry in
The Netherlands (showing an interaction between ma-
ternal smoking and high body mass index for the occur-
rence of specific congenital heart anomalies in offspring)
might serve as an example [34]. In general, these data-
bases allow for only a crude distinction between patient
groups, based on variables such as sociodemographic
characteristics, comorbidities, and concurrent medicine
use. The most important limitation of this strategy,
therefore, seems to be the lack of detailed information
on patient characteristics that might account for a dif-
ferential effect of treatment (such as smoking or body
mass index in the example given above). These routine
databases might nevertheless be a starting point for
generating hypotheses.
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sity issues that matter for health outcomes. First, qualita-
tive evidence might arise from observations by patients
and professionals, as they are the first to observe dif-
ferences in treatment outcomes. What differences are
observed? What causes these differences? Are there puz-
zling phenomena, unexpected side effects, or unidentified
variances in treatment effects? Physicians sometimes pub-
lish these valuable experiences as case reports. The experi-
ential knowledge of patients and the clinical experience of
health professionals have been shown to complement those
of researchers [35]. Second, scientific research that uses
qualitative methodology has been increasingly recognized
as making an important contribution to EBM. This in-
cludes studies that aim to understand why specific inter-
ventions tested in a RCT work, as well as studies that
generate hypotheses as to the potential differential effect of
an intervention to be tested in a RCT [36].
Once the diversity hypotheses have been identified, fur-
ther analysis and testing is needed. This could lead directly
to the recommendation to include subgroups in RCTs, but
also to aetiological studies to investigate possible under-
lying causes of the differences if these are unknown. The
development of diversity hypotheses as we propose here
might help to compensate for the above-mentioned weak-
ness of the subgroup analysis strategy, that of drawing mis-
leading conclusions: the more precisely the hypotheses as
to why groups might differ with regard to the intervention
effect are formulated before the data collection, the more
likely the study will result in valid estimates of differential
effects of the intervention. The subgroups to be involved
in the analyses can then be defined so that they have
aetiological consequences. For example, in the field of
hypertension, if ethnicity has been related to differences in
plasma renin levels as an effect modifier, future trials could
consider this as the relevant variable rather than ethnicity.
Institutional changes necessary to support this
methodological reform
The production of diversity-sensitive clinical knowledge
also requires institutional mechanisms and arrangements
that facilitate the methodological reform described above.
Although the role of funding agencies seems to be crucial
in this respect, we would like to point out the responsibil-
ities of other organizations as well.
Funding agencies
The NIH in the USA seems to have been most successful
in implementing specific diversity-relevant programmes.
Within the organizational structure of the NIH, offices
can be established to increase research on specific sub-
jects. To stimulate research on women’s health issues, the
NIH established the Office of Research on Women’s
Health (ORWH) in 1990. Other examples include theNational Institute on Minority Health and Health Dis-
parities (NIMHD) at the NIH [4]. In Europe, the focus
has been on mainstreaming rather than on specific
programmes. For example, as a follow up to a gender as-
sessment that was part of the Fifth Framework Programme
(FP5), that noted that projects addressing sex/gender dif-
ferences did so in a very limited way, the European Union
(EU) has commissioned the development of manuals for
scientific and project officers to provide them with
guidance on how to implement gender mainstreaming
throughout the entire process of funding research [37].
If diversity-relevant research is mainstreamed, funding
organizations should facilitate attention for this issue
throughout all working processes. This includes the pro-
cesses by which relevant committees review funding
proposals. At this stage, attention for diversity issues can
be facilitated by ensuring that all proposals include a
concise and systematic review of the relevant evidence
on diversity, that they specify how diversity in disease
aetiology, progression and manifestations, and treatment
outcomes has informed the study design, and that they
specify which of the other diversity issues that matter
will be analysed in the study.
The way diversity is conceptualized is crucial in this
respect. Both the NIH and the EU have chosen to focus
on broad subgroups, such as women or older people. In
line with our methodological recommendations, additional
dimensions of diversity require such mainstreaming.
In addition, there is a need for calls for proposals that allow
for multidisciplinary and multi-stakeholder programmes
aimed at producing a broader range of diversity-sensitive
clinical evidence, which is still lacking at present. These
programmes should include funding for innovative studies
that use a mix of qualitative and quantitative methods,
and which aim at generating and analysing diversity-
relevant hypotheses. The funding programmes should be
committed to further analyses and testing once relevant
diversity issues have been identified, with the overall aim of
producing better evidence on diversity to guide medical
practice.
Funding agencies in several countries have also devel-
oped guidance documents for researchers to enhance the
quality of research among subgroups, such as minority
populations. The effectiveness of this kind of guidance,
which contains methodological and practical recommenda-
tions, has not been studied widely. Recent experiences
from a major funder of social science research in the UK
suggest that this guidance has little impact on practice.
The authors conclude that in order to have an impact, this
guidance needs to be promoted more vigorously [38].
Other stakeholders
Apart from funding agencies, other stakeholders also
seem to be vitally important. These include (but are not
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tient organizations, and medical ethics committees.
Researchers should design studies more carefully to
allow for the analysis of diversity issues that matter, as de-
scribed in the first part of this paper. In determining end-
points for their studies, they need to more systematically
consider diversity in aetiology as well as manifestation and
progression of disease. In defining diversity issues that
matter, they should in fact consider all relevant factors that
may influence the efficacy of health care.
The professional organizations of general practitioners
and specialists tend to identify gaps in diversity-sensitive
evidence when developing treatment guidelines. The
gaps can guide research programmes. They can also help
to identify the underlying philosophical assumptions of the
observations of current research, as well as generate
hypotheses on diversity issues that matter from clinical
observations.
Patient organizations can also play a key role in identi-
fying diversity issues. Funding agencies increasingly have
patient representatives on their committees, which often
raises issues about representation. Who can be consid-
ered to represent a specific patient population or com-
munity? The position developed by INVOLVE, a British
advisory board that supports greater public involvement
in health research, is that involvement of patients or
consumers should not aim to represent users, but to
seek different perspectives: involving a range of people
introduces a range of perspectives [39]. Although con-
sumer involvement in the design of trials (such as in the
UK) has increased over time, most trials still have no
such involvement [40]. In addition, although researchers
feel that the contribution of consumers is worthwhile,
there seems to be room for improvement regarding the
impact consumers have on the way research questions
are being framed, including aspects of diversity [40].
Medical ethics committees can play a key role as well
[41]. Historically, ethical debates in clinical research have
focused on patient protection, expressed mainly as doing
no harm, and autonomy in decision making. Increas-
ingly, such committees are considering participation and
representation in clinical research. An important issue,
therefore, is to consider barriers to participation, how
these may differ between patient groups, and how access
to research can be achieved.
Conclusions
The importance of producing diversity-sensitive evidence
for the development of guidelines for clinical care has
been acknowledged for decades. Solutions have focused
mainly on including under-represented groups in trials.
Although this issue is still of the utmost importance, the
production of diversity-sensitive clinical evidence re-
quires more than just this. We argue that heterogeneityshould be the starting point of clinical trials, implying an
exploration of diversity issues that matter for the out-
come of health care services. To produce the evidence
that justifies clinical trials that take diversity issues into
account, a mix of hypothesis-generating and hypothesis-
testing research is needed, involving studies that use a
mixed-methods approach. Confronting diversity in clin-
ical research thus demands a programmatic and iterative
approach that ensures an ongoing interest in relevant
variance. Stakeholder participation is key. Doctors and
patients can alert the researchers to diversity issues that
matter in routine health care, thus contributing to a
more relevant evidence base for practice. In addition, a
broad conceptualization of diversity is crucial in this
respect. In analysing diversity in treatment outcomes,
the design of RCTs needs to be based on a nuanced un-
derstanding of the interplay of the factors underlying
patients’ background characteristics, including genetic,
environmental, sociocultural, economic, and behavioural
factors. This methodological reform can only be achieved
if it is supported by institutional changes. Diversity issues
need to be mainstreamed into all phases of funding
programmes for health research, from commissioning
to implementation. In addition, many other actors, includ-
ing professional organizations and medical ethics commit-
tees, should incorporate diversity as a core value in the way
they operate.
We hope our reflections will inspire others who take
diversity in the production of clinical evidence seriously.
This trajectory is essential, so that the further develop-
ment of EBM will benefit all patients.
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